Synthesis, molecular modelling and enzymatic evaluation of (±)3,5-diphenyl-2-thioxoimidazolidin-4-ones as new potential cyclooxygenase inhibitors

Bioorganic and Medicinal Chemistry

Volumn 14, Issue 4, 2006, Pages 918-927

  Gauthier, Marie P ^a   Michaux, Catherine ^a   Rolin, Stéphanie ^a   Vastersaegher, Caroline ^a   De Leval, Xavier ^b   Julémont, Fabien ^b   Pochet, Lionel ^a   Masereel, Bernard ^a  

^a UNIVERSITY OF NAMUR   (Belgium)

^b UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

2 Thioxoimidazolin 4 ones; COX inhibition; Human COX 2; Ovine COX 1

Indexed keywords

3 (3 BROMOPHENYL) 5 PHENYL 2 THIOXOIMIDAZOLIDIN 4 ONE; 3 (3 CHLOROPHENYL) 5 PHENYL 2 THIOXOIMIDAZOLIDIN 4 ONE; 3 (3 FLUOROPHENYL 5 PHENYL) 2 THIOXOIMIDAZOLIDIN 4 ONE; 3 (3 IODOPHENYL) 5 PHENYL 2 THIOXOIMIDAZOLIDIN 4 ONE; 3 (3 METHOXYPHENYL) 5 PHENYL 2 THIOXOIMIDAZOLIDIN 4 ONE; 3 (3 METHYLPHENYL) 5 PHENYL 2 THIOXOIMIDAZOLIDIN 4 ONE; 3 (4 BROMOPHENYL) 5 PHENYL 2 THIOXOIMIDAZOLIDIN 4 ONE; 3 (4 CHLOROPHENYL) 5 PHENYL 2 THIOXOIMIDAZOLIDIN 4 ONE; 3 (4 ETHYLPHENYL) 5 PHENYL 2 THIOXOIMIDAZOLIDIN 4 ONE; 3 (4 FLUOROPHENYL) 5 PHENYL 2 THIOXOIMIDAZOLIDIN 4 ONE; 3 (4 IODOPHENYL) 5 PHENYL 2 THIOXOIMIDAZOLIDIN 4 ONE; 3 (4 METHYLPHENYL) 5 PHENYL 2 THIOXOIMIDAZOLIDIN 4 ONE; 3 (4 NITROPHENYL) 5 PHENYL 2 THIOXOIMIDAZOLIDIN 4 ONE; 3 [3 (METHYLSULFONYL)PHENYL] 5 PHENYL 2 THIOXOIMIDAZOLIDIN 4 ONE; 3 [4 (AMINOSULFONYL)PHENYL] 5 PHENYL 2 THIOXOIMIDAZOLIDIN 4 ONE; 3 [4 (METHYLSULFONYL)PHENYL] 5 PHENYL 2 THIOXOIMIDAZOLIDIN 4 ONE; 3,5 DIPHENYL 2 THIOXOIMIDAZOLIDIN 4 ONE; 3,5 DIPHENYL 2 THIOXOIMIDAZOLIDIN 4 ONE DERIVATIVE; 5 PHENYL 2 THIOXO 3 [3 (TRIFLUOROMETHYL)PHENYL]IMIDAZOLIDIN 4 ONE; 5 PHENYL 2 THIOXO 3 [4 (TRIFLUOROMETHYL)PHENYL]IMIDAZOLIDIN 4 ONE; CELECOXIB; CYCLOOXYGENASE 2; ETORICOXIB; IMIDAZOLINE DERIVATIVE; LIPOPOLYSACCHARIDE; NIMESULIDE; PROSTAGLANDIN SYNTHASE INHIBITOR; RECOMBINANT ENZYME; ROFECOXIB; UNCLASSIFIED DRUG; VALDECOXIB;

ARTHRITIS; ARTICLE; CANCER; CONTROLLED STUDY; DRUG ACTIVITY; DRUG DESIGN; DRUG HALF LIFE; DRUG SCREENING; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN; MOLECULAR MODEL; PROTEIN EXPRESSION; RHEUMATIC FEVER;

CYCLOOXYGENASE INHIBITORS; HUMANS; IMIDAZOLIDINES; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; STRUCTURE-ACTIVITY RELATIONSHIP;

OVIS;

EID: 30344431808     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmc.2005.09.005     Document Type: Article

References (44)

1. W.L. Smith The eicosanoids and their biochemical mechanisms of action Biochem. J. 259 1989 315
2. S.H. Lee, E. Soyoola, P. Chanmugam, S. Hart, W. Sun, H. Zhong, S. Liou, D. Simmons, and D. Hwang Selective expression of mitogen-inducible cyclooxygenase in macrophages stimulated with lipopolysaccharide J. Biol. Chem. 267 1992 25934
3. J.A. Maier, T. Hla, and T. Maciag Cyclooxygenase is an immediate-early gene induced by interleukin-1 in human endothelial cells J. Biol. Chem. 265 1990 10805
4. J. Sirois, and J.S. Richards Purification and characterization of a novel, distinct isoform of prostaglandin endoperoxide synthase induced by human chorionic gonadotropin in granulosa cells of rat preovulatory follicles J. Biol. Chem. 267 1992 6382
5. H. Kawaguchi, C.C. Pilbeam, G. Gronowicz, C. Abreu, B.S. Fletcher, H.R. Herschman, L.G. Raisz, and M.M. Hurley Transcriptional induction of prostaglandin G/H synthase-2 by basic fibroblast growth factor J. Clin. Invest. 96 1995 923
6. W. Xie, and H.R. Herschman Transcriptional regulation of prostaglandin synthase 2 gene expression by platelet-derived growth factor and serum J. Biol. Chem. 271 1996 31742
7. W.L. Xie, J.G. Chipman, D.L. Robertson, R.L. Erikson, and D.L. Simmons Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing Proc. Natl. Acad. Sci. U.S.A. 88 1991 2692
8. A.J. Dannenberg, N.K. Altorki, J.O. Boyle, C. Dang, L.R. Howe, B.B. Weksler, and K. Subbaramaiah Cyclo-oxygenase 2: a pharmacological target for the prevention of cancer Lancet Oncol. 2 2001 544
9. S.J. Shiff, P. Shivaprasad, and D.L. Santini Cyclooxygenase inhibitors: drugs for cancer prevention Curr. Opin. Pharmacol. 3 2003 352
10. K.M. Leahy, A.T. Koki, and J.L. Masferrer Role of cyclooxygenases in angiogenesis Curr. Med. Chem. 7 2000 1163
11. J.L. Masferrer, K.M. Leahy, A.T. Koki, B.S. Zweifel, S.L. Settle, B.M. Woerner, D.A. Edwards, A.G. Flickinger, R.J. Moore, and K. Seibert Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors Cancer Res. 60 2000 1306
12. J.J. Hoozemans, R. Veerhuis, A.J. Rozemuller, and P. Eikelenboom Non-steroidal anti-inflammatory drugs and cyclooxygenase in Alzheimer's disease Curr. Drug Targets 4 2003 461
13. P. Teismann, K. Tieu, D.K. Choi, D.C. Wu, A. Naini, S. Hunot, M. Vila, V. Jackson-Lewis, and S. Przedborski Cyclooxygenase-2 is instrumental in Parkinson's disease neurodegeneration Proc. Natl. Acad. Sci. U.S.A. 100 2003 5473
14. G. Dannhardt, and W. Kiefer Cyclooxygenase inhibitors-current status and future prospects Eur. J. Med. Chem. 36 2001 109
15. M.J. Uddin, P.N. Praveen Rao, R. McDonald, and E.E. Knaus A new class of acyclic 2-alkyl-1,1,2-triaryl (Z)-olefins as selective cyclooxygenase-2 inhibitors J. Med. Chem. 7 2004 6108
16. S.R. Bertenshaw, J.J. Talley, D.J. Rogier, M.J. Graneto, R.S. Rogers, S.W. Kramer, T. Penning, C.M. Koboldt, A.W. Veenhuizen, Y. Zhang, and W.E. Perkins 3,4-Diarylthiophenes are selective COX-2 inhibitors Bioorg. Med. Chem. Lett. 5 1995 2919
17. C.S. Li, W.C. Black, C. Brideau, C.C. Chan, S. Charleson, W.A. Cromlish, D. Claveau, J.Y. Gauthier, R. Gordon, G. Greig, E. Grimm, J. Guay, C.K. Lau, D. Riendeau, M. Thérien, D.M. Visco, E. Wong, L. Xu, and P. Prasit A new structural variation on the methanesulfonylphenyl class of selective cyclooxygenase-2 inhibitors Bioorg. Med. Chem. Lett. 9 1999 3181
18. T.D. Penning, J.J. Talley, S.R. Bertenshaw, J.S. Carter, P.W. Collins, S. Docter, M.J. Graneto, L.F. Lee, J.W. Malecha, J.M. Miyashiro, R.S. Rogers, D.J. Rogier, S.S. Yu, G.D. Anderson, E.G. Burton, J.N. Cogburn, S.A. Gregory, C.M. Koboldt, W.E. Perkins, K. Seibert, A.W. Veenhuizen, Y.Y. Zhang, and P.C. Isakson Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3- (trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib) J. Med. Chem. 40 1997 1347
19. H. Hashimoto, K. Imamura, J. Haruta, and K. Wakitani 4-(4-Cycloalkyl/ aryl-oxazol-5-yl)benzenesulfonamides as selective cyclooxygenase-2 inhibitors: enhancement of the selectivity by introduction of a fluorine atom and identification of a potent, highly selective, and orally active COX-2 inhibitor JTE-522 J. Med. Chem. 45 2002 1511
20. J.J. Talley, D.L. Brown, J.S. Carter, M.J. Graneto, C.M. Koboldt, J.L. Masferrer, W.E. Perkins, R.S. Rogers, A.F. Shaffer, Y.Y. Zhang, B.S. Zweifel, and K. Seibert 4-[5-Methyl-3-phenylisoxazol-4-yl]-benzenesulfonamide, valdecoxib: a potent and selective inhibitor of COX-2 J. Med. Chem. 43 2000 775
21. J.J. Talley, S.R. Bertenshaw, D.L. Brown, J.S. Carter, M.J. Graneto, M.S. Kellogg, C.M. Koboldt, J. Yuan, Y.Y. Zhang, and K. Seibert N-[[(5-Methyl-3- phenylisoxazol-4-yl)-phenyl]sulfonyl]propanamide, sodium salt, parecoxib sodium: a potent and selective inhibitor of COX-2 for parenteral administration J. Med. Chem. 43 2000 1661
22. J.S. Carter, S. Kramer, J.J. Talley, T. Penning, P. Collins, M.J. Graneto, K. Seibert, C.M. Koboldt, J. Masferrer, and B. Zweifel Synthesis and activity of sulfonamide-substituted 4,5-diaryl thiazoles as selective cyclooxygenase-2 inhibitors Bioorg. Med. Chem. Lett. 9 1999 1171
23. C. Almansa, J. Alfon, A.F. de Arriba, F.L. Cavalcanti, I. Escamilla, L.A. Gomez, A. Miralles, R. Soliva, J. Bartroli, E. Carceller, M. Merlos, and J. Garcia-Rafanell Synthesis and structure-activity relationship of a new series of COX-2 selective inhibitors: 1,5-diarylimidazoles J. Med. Chem. 46 2003 3463
24. I.K. Khanna, R.M. Weier, Y. Yu, X.D. Xu, F.J. Koszyk, P.W. Collins, C.M. Koboldt, A.W. Veenhuizen, W.E. Perkins, J.J. Casler, J.L. Masferrer, Y.Y. Zhang, S.A. Gregory, K. Seibert, and P.C. Isakson 1,2-Diarylimidazoles as potent, cyclooxygenase-2 selective, and orally active antiinflammatory agents J. Med. Chem. 40 1997 1634
25. G. Dannhardt, W. Kiefer, G. Kramer, S. Maehrlein, U. Nowe, and B. Fiebich The pyrrole moiety as a template for COX-1/COX-2 inhibitors Eur. J. Med. Chem. 35 2000 499
26. C. Puig, M.I. Crespo, N. Godessart, J. Feixas, J. Ibarzo, J.M. Jimenez, L. Soca, I. Cardelus, A. Heredia, M. Miralpeix, J. Puig, J. Beleta, J.M. Huerta, M. Lopez, V. Segarra, H. Ryder, and J.M. Palacios Synthesis and biological evaluation of 3,4-diaryloxazolones: a new class of orally active cyclooxygenase-2 inhibitors J. Med. Chem. 43 2000 214
27. R.W. Friesen, C. Brideau, C.C. Chan, S. Charleson, D. Deschenes, D. Dube, D. Ethier, R. Fortin, J.Y. Gauthier, Y. Girard, R. Gordon, G. Greig, D. Riendeau, C. Savoie, Z. Wang, and E. Wong 2-Pyridinyl-3-(4-methylsulfonyl) phenylpyridines: selective and orally active cyclooxygenase-2 inhibitors Bioorg. Med. Chem. Lett. 8 1998 2777
28. C.S. Li, C. Brideau, C.C. Chan, C. Savoie, D. Claveau, S. Charleson, R. Gordon, G. Greig, J.Y. Gauthier, C.K. Lau, D. Riendeau, M. Therien, E. Wong, and P. Prasit Pyridazinones as selective cyclooxygenase-2 inhibitors Bioorg. Med. Chem. Lett. 13 2003 597
29. Y.H. Joo, J.K. Kim, S.-H. Kang, M.S. Noh, J.-Y. Ha, J.K. Choi, K.M. Lim, and S. Chung 2,3-Diarylpyran-4-ones: a new series of selective cyclooxygenase-2 inhibitors Bioorg. Med. Chem. Lett. 14 2004 2195
30. E. Ortiz Market withdrawal of Vioxx: is it time to rethink the use of COX-2 inhibitors? J. Manag. Care Pharm. 10 2004 551
31. B. Sibbald Rofecoxib (Vioxx) voluntarily withdrawn from market Can. Med. Assoc. J. 171 2004 1027
32. P. Edman Preparation of phenyl thiohydantoins from some natural amino acids Acta Chem. Scand. 4 1950 277
33. A.L. Lopez, and G.G. Trigo The chemistry of hydantoins Adv. Heterocycl. Chem. 38 1985 177
34. H.A. Staab, and G. Walther Synthese von isothiocyanaten Liebigs Ann. Chem. 657 1962 104
35. C. Michaux, and C. Charlier Structural approach for COX-2 inhibition Mini Rev. Med. Chem. 4 2004 603
36. G.M. Morris, D.S. Goodsell, R.S. Halliday, R. Huey, W.E. Hart, R.K. Belew, and A.J. Olson Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function J. Comput. Chem. 19 1998 1639
37. Jones, G.; Willett, P.; Glen, R. C.; Leach, A. R.; Taylor, R. Gold, 1.2 ed.; Astex Technology, Cambridge, UK.
38. Hart, T. N., Ness, S. R. Dockvision, 1.0.3 ed.; Alberta.
39. Accelrys, Discover3, 2.98 ed.; Accelrys Inc., San Diego.
40. R. Garcia-Nieto, C. Perez, and F. Gago Automated docking and molecular dynamics simulations of nimesulide in the cyclooxygenase active site of human prostaglandin-endoperoxide synthase-2 (COX-2) J. Comput. Aided Mol. Des. 14 2000 147
41. R.G. Kurumbail, A.M. Stevens, J.K. Gierse, J.J. McDonald, R.A. Stegeman, J.Y. Pak, D. Gildehaus, J.M. Miyashiro, T.D. Penning, K. Seibert, P.C. Isakson, and W.C. Stallings Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents Nature 384 1996 644
42. T.D. Warner, F. Giuliano, I. Vojnovic, A. Bukasa, J.A. Mitchell, and J.R. Vane Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis Proc. Natl. Acad. Sci. U.S.A. 96 1999 7563
43. Biosym/MSI; InsightII, 97.0 ed.; Homology, Molecular simulations Inc.
44. X. de Leval, J. Delarge, P. Devel, P. Neven, C. Michaux, B. Masereel, B. Pirotte, J.L. David, Y. Henrotin, and J.M. Dogné Evaluation of classical NSAIDs and COX-2 selective inhibitors on purified ovine enzymes and human whole blood Prostaglandins Leukot. Essent. Fatty Acids 64 2001 211